Review Article
Nanomedicine for Inner Ear Diseases: A Review of Recent In Vivo Studies
Table 3
Studies attempting to deliver growth factors to the inner ear using nanoparticles.
| Nanoparticle | Size of nanoparticle | Animal | Administration route | Loaded drug or gene | Evaluation time | Evaluation of nanoparticle uptake |
| Silica supraparticle [29, 30] | 500 μm (porous structure) | Deafened guinea pigs | Intracochlear | BDNF | At 4 weeks | Survival of SGNs |
| Phytantriol lipid-based crystalline NP [31] | 215.6~227.2 nm | Guinea pigs, deafened with cisplatin | Intratympanic | NGF | At several predetermined time points within 24 h | ELISA assay of cochlear fluid |
| Nanoporous PGA NP [32] | 1.8–3.2 μm | Guinea pig, deafened with aminoglycoside | Intracochlear | BDNF | At 20 days | Morphology |
|
|
BDNF: brain-derived neurotrophic factor; SGN: spiral ganglion neurons; NP: nanoparticle; NGF: nerve growth factor; PGA: poly(L-glutamic acid).
|